Clinical Trial Update: Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen [Phase 3]

View source ↗

Summary

This update notes the completion of a Phase 3 trial evaluating early access to cabazitaxel in metastatic hormone-refractory prostate cancer patients previously …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Jevtana (cabazitaxel)

Snippet

Sponsor: Sanofi | Conditions: Prostate Cancer Metastatic | Phase 3 | Status: COMPLETED